Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.